
~ PEDMARQSI is the First and Only Approved Therapy in the EU and U.K. for the Prevention of Ototoxicity, or Hearing Loss, Induced by Cisplatin Chemotherapy in Patients 1 month to <18 Years of...
~ PEDMARQSI® (anhydrous sodium thiosulfate) is the first and only treatment available within NHS England and Wales for the prevention of cisplatin-induced ototoxicity (hearing loss) in children...
~ $13 Million Convertible Debt Repayment from Available Cash ~ ~ Elimination of Approximately $1.5 Million in Annual Interest Expense and Potential Equity Overhang of Approximately 1.6 Million...
RESEARCH TRIANGLE PARK, N.C., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the...
RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the...
~ Achieved Third Quarter 2024 Net Product Sales of $7.0 Million ~ ~ Increasing Momentum and Successful Reimbursement in the Adolescent and Young Adult (AYA) Segment Following Strategic...
RESEARCH TRIANGLE PARK, N.C., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that...
~ Pierre S. Sayad, PhD, M.S., Appointed Chief Medical Officer ~ ~ Terry Evans Appointed Chief Commercial Officer ~ ~ Christiana Cioffi, MBA, Appointed Chief Strategy Officer ~ RESEARCH TRIANGLE...
RESEARCH TRIANGLE PARK, N.C., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that...
~ Achieved Second Quarter 2024 Total Net Revenues of $7.3 Million ~ ~ Appointed Jeffrey S. Hackman as Chief Executive Officer (CEO) and Member of the Board of Directors ~ ~ Company Has...
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.28 | -2.87474332649 | 9.74 | 9.74 | 9.02 | 294 | 9.42832653 | CS |
4 | 1.16 | 13.9759036145 | 8.3 | 9.74 | 7.8 | 1844 | 9.2305553 | CS |
12 | 3.78 | 66.5492957746 | 5.68 | 9.74 | 5.68 | 2139 | 8.50388766 | CS |
26 | 1.22 | 14.8058252427 | 8.24 | 9.74 | 5.65 | 1944 | 7.49010636 | CS |
52 | -3.94 | -29.4029850746 | 13.4 | 15.2 | 5.65 | 1545 | 8.31838735 | CS |
156 | 2.87 | 43.5508345979 | 6.59 | 15.43 | 5.65 | 887 | 9.48596719 | CS |
260 | -0.19 | -1.9689119171 | 9.65 | 15.43 | 4.95 | 1046 | 9.19694535 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales